Retirement Planning Co of New England Inc. Purchases Shares of 4,500 Hologic, Inc. $HOLX

Key Points

• Retirement Planning Co of New England Inc. has acquired a new stake in Hologic, Inc., purchasing 4,500 shares valued at approximately $278,000 during the first quarter.
• Institutional investors own 94.73% of Hologic's stock, with significant increases in holdings seen from multiple firms, including a 34.4% boost from Victory Capital Management.
• Hologic reported a quarterly EPS of $1.08, exceeding analysts' expectations, and set a forecast for the upcoming quarters with strong growth indicators.

Retirement Planning Co of New England Inc. purchased a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 4,500 shares of the medical equipment provider's stock, valued at approximately $278,000.

Other large investors also recently modified their holdings of the company. Zions Bancorporation National Association UT bought a new position in Hologic during the 1st quarter worth $34,000. Allworth Financial LP raised its position in Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 216 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in Hologic during the 1st quarter worth $42,000. Larson Financial Group LLC raised its position in Hologic by 6,016.7% during the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 722 shares during the last quarter. Finally, Raiffeisen Bank International AG bought a new position in Hologic during the 4th quarter worth $49,000. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Up 0.6%

Shares of HOLX traded up $0.37 during trading hours on Friday, hitting $66.76. The stock had a trading volume of 1,270,243 shares, compared to its average volume of 1,601,091. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The firm has a 50 day simple moving average of $66.34 and a 200-day simple moving average of $62.61. The firm has a market capitalization of $14.85 billion, a P/E ratio of 27.70, a price-to-earnings-growth ratio of 2.41 and a beta of 0.57. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm's revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period last year, the business posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Argus upgraded Hologic from a "hold" rating to a "buy" rating and set a $80.00 price target for the company in a report on Monday, August 18th. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a report on Saturday, August 30th. Evercore ISI increased their price target on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a report on Tuesday, July 8th. Royal Bank Of Canada upgraded Hologic from a "sector perform" rating to an "outperform" rating and increased their price target for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. Finally, Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and increased their price target for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.